Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 18

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
,138 and 11,761,030. On July 25, 2025, the PTAB denied institution of Curio’s IPRs for U.S. Patent Nos. 10,662,468 and 11,001,879.On December 4, 2023, the Company filed a request for a preliminary injunction in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe EP Patent No. 2697391 (the “EP 391 patent”). A hearing was held on March 26, 2024. On April 30, 2024, the UPC granted the Company’s request and issued a preliminary injunction requiring Curio to stop offering, marketing, using or possessing these Curio Seeker products and services in Germany, France and Sweden. Curio did not appeal the preliminary injunction. On March 25, 2024, the Company filed a main request in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe the EP 391 patent. A hearing in the main action took place in May 2025. On June 14, 2025, the UPC found that Curio directly infringes claim 14 of the EP 391 patent and issued a permanent injunction ordering Curio to cease and desist from selling the Seeker products in Germany, France, and Sweden.

6.    Capital Stock

As of June 30, 2025, the number of shares of Class A common stock and Class B common stock issued and outstanding were 114,363,260 and 10,078,872, respectively.

15

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods:Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Class B common stock converted to Class A common stock 3,977,961 — 3,977,961 — 

 7.    Equity Incentive Plans

Stock-based CompensationThe Company recorded stock-based compensation cost for the periods presented as follows (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Cost of revenue